A novel weight-loss medication has shown remarkable success in alleviating knee discomfort and improving physical function in patients with knee osteoarthritis, according to findings from two significant clinical trials. This investigational drug not only reduced pain but also induced considerable weight loss, a known factor in mitigating arthritis symptoms. Despite these promising outcomes, higher dosages were associated with increased side effects, and the long-term implications for joint health remain an area for continued research.

Obesity is a significant contributor to the development and progression of knee osteoarthritis, primarily by increasing mechanical stress on the joints and promoting low-grade systemic inflammation. Consequently, weight reduction is a crucial aspect of managing knee osteoarthritis in individuals with excess body weight. Previous studies have indicated that GLP-1 receptor agonists, such as semaglutide, can effectively induce weight loss and improve metabolic health, with some evidence suggesting a positive impact on knee pain.

Retatrutide is an injectable treatment administered once weekly, designed to activate three distinct hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. Earlier phase 2 trials had already demonstrated its potential to achieve substantial weight loss, with reductions of up to 24.2% over 48 weeks. The recent phase 3 trials aimed to further evaluate the drug's effects on knee pain in conjunction with this weight loss.

Eli Lilly, the pharmaceutical company developing Retatrutide, sponsored the two double-blind, randomized, placebo-controlled phase 3 trials: TRIUMPH-4 and TRIUMPH-1-OA. Participants in TRIUMPH-4 included adults without diabetes who experienced chronic knee pain and had X-ray confirmed osteoarthritis, along with a body mass index (BMI) of at least 27. TRIUMPH-1-OA enrolled participants with a BMI of at least 30, or at least 27 with an obesity-related complication. TRIUMPH-4 involved 445 participants who received either 9 mg, 12 mg of Retatrutide, or a placebo for 68 weeks. TRIUMPH-1-OA included 574 participants who were administered 4 mg, 9 mg, 12 mg of the drug, or a placebo, for 80 weeks. The treatment regimen began with a 2 mg dose, which was progressively increased every four weeks until the target dose was reached. The primary endpoints for both trials included changes in knee pain, measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and for TRIUMPH-4, also included the percentage change in body weight.

Both trials consistently demonstrated that Retatrutide significantly alleviated knee pain in participants, with improvements notably surpassing those observed in the placebo groups. In the TRIUMPH-4 trial, patients treated with Retatrutide experienced pain reductions of approximately 3.7 to 4 points on the 10-point WOMAC scale after 68 weeks, compared to just over 2 points in the placebo group. This translates to an additional improvement of about 1.6 to 1.8 points over placebo, with statistically significant benefits at both tested doses. Similarly, in TRIUMPH-1-OA, all three Retatrutide doses led to significant reductions in knee pain after 80 weeks, with participants showing improvements of approximately 3.2 to 3.6 points, versus 1.9 points in the placebo group. The additional pain reduction ranged from 1.35 to 1.77 points, indicating moderate to large treatment effects. Physical function scores on the WOMAC scale also mirrored these improvements, showing differences of roughly 1.7 to 1.95 points compared to placebo. Analysis of combined data at week 68 revealed that an estimated 63% to 70% of Retatrutide recipients achieved at least a 50% reduction in pain, in contrast to 38% in the placebo group. For physical function, the corresponding figures were 63.5% to 64.6% against 33.1% for placebo.

Furthermore, Retatrutide demonstrated considerable weight loss across both trials. In TRIUMPH-4, the 9 mg group saw a 20.0% reduction in body weight, while the 12 mg group experienced a 23.7% reduction, significantly higher than the 4.6% reduction in the placebo group. A remarkable 90% to 95% of Retatrutide participants achieved at least a 5% body weight loss. In TRIUMPH-1-OA, weight reductions of 17.5%, 22.9%, and 24.8% were observed in the 4 mg, 9 mg, and 12 mg groups, respectively, compared to 4.3% in the placebo group. In TRIUMPH-4, approximately 33.7% of participants on 9 mg Retatrutide and 45.1% on 12 mg lost 25% or more of their baseline weight, versus only 3.1% in the placebo group. However, higher doses of Retatrutide were associated with increased rates of serious adverse events. In TRIUMPH-4, approximately 10% to 11% of participants receiving 9 mg or 12 mg experienced serious adverse events, compared to 2% in the placebo group. In TRIUMPH-1-OA, these rates ranged from 4.2% at 4 mg to 14.6% at 12 mg, versus 6.9% in the placebo group. Gastrointestinal symptoms, including nausea, diarrhea, and constipation, were the most frequently reported side effects. Despite being generally mild to moderate, they accounted for a significant proportion of treatment discontinuations. Dysesthesia, an abnormal skin sensation, was also more common with Retatrutide. Two deaths occurred in TRIUMPH-4, though neither was deemed treatment-related. Cancer events were reported without a clear dose-related pattern, and the trials were not designed to assess cancer risk.

The pain relief provided by Retatrutide potentially offers a favorable comparison to existing treatments, with effect sizes that align with or exceed those of ibuprofen, tramadol, and intra-articular steroid injections. Researchers hypothesize that the pain reduction stems partly from decreased joint loading due to weight loss and possibly from anti-inflammatory effects, though the precise mechanisms require further investigation. A notable limitation of the study was the initial pain assessment occurring at week 16, leaving the exact onset speed of the drug's action unclear. Additionally, inflammatory markers were only measured at the start and end of the trial. The generalizability of these findings is limited to overweight or obese individuals with osteoarthritis. The trials were not structured to determine if Retatrutide can slow joint damage or prevent the need for knee replacement surgery. Furthermore, whether the improvements persist after treatment cessation remains unknown. The dropout rate was considerable, with only 72% completing assigned treatment in TRIUMPH-4 and 75% in TRIUMPH-1-OA, suggesting challenges in treatment adherence.

In conclusion, for individuals grappling with obesity and chronic knee osteoarthritis, Retatrutide demonstrated substantial benefits in reducing pain and enhancing physical capabilities, accompanied by significant weight loss. Nevertheless, the elevated incidence of adverse events, particularly at higher doses, and the unresolved questions regarding long-term joint health necessitate a cautious approach and further detailed investigation into its comprehensive safety and efficacy profile.